Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

被引：4324

作者：

Atkinson, AJ

Colburn, WA

DeGruttola, VG

DeMets, DL

Downing, GJ

Hoth, DF

Oates, JA

Peck, CC

Schooley, RT

Spilker, BA

Woodcock, J

Zeger, SL

机构：

[1] NIH, Off Sci Policy, Bethesda, MD 20892 USA

[2] NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA

[3] MDS Harris Inc, Phoenix, AZ USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Univ Wisconsin, Dept Biostat, Madison, WI USA

[6] Axys Pharmaceut, San Francisco, CA USA

[7] Vanderbilt Univ, Dept Med, Nashville, TN USA

[8] Georgetown Univ, Ctr Drug Dev Sci, Washington, DC USA

[9] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA

[10] Pharmaceut Res & Manufacturers Amer, Washington, DC USA

[11] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

[12] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 03期

关键词：

D O I：

10.1067/mcp.2000.113989

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：89 / 95

页数：7

共 30 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

[Anonymous], 1991, JAMA, V265, P3255

[3] Efficacy measures: Surrogates or clinical outcomes? [J].

Blue, JW ;

Colburn, WA .

JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (09) :767-770

[4] SURROGATE END-POINTS - A BASIS FOR A RATIONAL APPROACH [J].

BOISSEL, JP ;

COLLET, JP ;

MOLEUR, P ;

HAUGH, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (03) :235-244

[5]

CARR G, 1998, ECONOMIST, V346, P1

[6] Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer [J].

Ciarmiello, A ;

Del Vecchio, S ;

Silvestro, P ;

Potena, MI ;

Carriero, MV ;

Thomas, R ;

Botti, G ;

D'Aiuto, G ;

Salvatore, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1677-1683

[7]

Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.3.CO

[8]

2-D

[9] Importance of surrogate markers in evaluation of antiviral therapy for HIV infection [J].

Deyton, L .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :159-160

[10] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].

ECHT, DS ;

LIEBSON, PR ;

MITCHELL, LB ;

PETERS, RW ;

OBIASMANNO, D ;

BARKER, AH ;

ARENSBERG, D ;

BAKER, A ;

FRIEDMAN, L ;

GREENE, HL ;

HUTHER, ML ;

RICHARDSON, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788

← 1 2 3 →